HTR1A and age-related macular degeneration: In this study we report that the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT), is able to reduce the accumulation of both autophagic-derived and photoreceptor outer segment-derived lipofuscin, increase antioxidant protection and reduce oxidative damage in cultured human RPE cells as well as being able to reduce lipofuscin accumulation and improve visual function in an animal model of AMD.